Reassurance for continuous dabigatran in AF ablation: RE-CIRCUIT

Lingering concerns about the use of continuous dabigatran (Pradaxa) for atrial fibrillation catheter ablations have now been put to rest say experts following the release of new data at the American College of Cardiology conference this week. The findings from the RE-CIRCUIT trial presented in a late breaking session and published simultaneously in the New ...

Already a member?

Login to keep reading.

© 2021 the limbic